Jaclynn Do, MD
Family Medicine · Garden Grove, CANPI 1366439051
Payments from drug & device makers
Across 121 payments — averaging $38.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Amgen$858
- AstraZeneca$402
- Johnson & Johnson$360
- Boehringer Ingelheim$314
- Lilly USA, LLC$296
- plus $1K from 20 others
What the payments were for
- Consulting fees$1,20026%
- Food & beverage$3,45674%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| Amgen | 28 | $858 |
| AstraZeneca | 16 | $402 |
| Johnson & Johnson(2 entities) | 10 | $360 |
| Boehringer Ingelheim | 8 | $314 |
| Lilly USA, LLC | 9 | $296 |
| AbbVie(2 entities) | 7 | $236 |
| Merck | 7 | $133 |
| Gilead | 1 | $119 |
| Aimmune Therapeutics, Inc. | 4 | $101 |
| GSK | 4 | $100 |
| Dexcom, Inc. | 1 | $80 |
| Sunovion Pharmaceuticals Inc. | 5 | $66 |
| Acadia Pharmaceuticals Inc | 3 | $57 |
| Novo Nordisk | 3 | $56 |
| Amarin Pharma, Inc. | 2 | $43 |
| Pfizer | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Shield Therapeutics Inc | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Genentech USA, Inc. | 1 | $14 |
| Endogastric Solutions, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,661 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 211 | $191,528 |
| TrulicityDulaglutide | 106 | $151,387 |
| OtezlaApremilast | 13 | $66,192 |
| TradjentaLinagliptin | 85 | $63,658 |
| JanuviaSitagliptin Phosphate | 78 | $61,510 |
| VascepaIcosapent Ethyl | 67 | $36,653 |
| RestasisCyclosporine | 28 | $20,517 |
| FarxigaDapagliflozin Propanediol | 18 | $17,884 |
| ZenpepLipase/Protease/Amylase | 20 | $17,623 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,419 |
| OzempicSemaglutide | 11 | $15,627 |
| EliquisApixaban | 16 | $15,572 |
| LinzessLinaclotide | 15 | $9,565 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,726 |
| Diclofenac Sodium | 21 | $5,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $314 | $255,186296 claims |
| Lilly USA, LLCTrulicity | $296 | $151,387106 claims |
| AmgenOtezla | $858 | $66,19213 claims |
| MerckJanuvia | $133 | $61,51078 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $100 | $34,30175 claims |
| AbbVieRestasis, Linzess | $236 | $30,08243 claims |
| AstraZenecaFarxiga | $402 | $17,88418 claims |
| Aimmune Therapeutics, Inc.Zenpep | $101 | $17,62320 claims |
| Novo NordiskOzempic | $56 | $15,62711 claims |
| PfizerEliquis | $37 | $15,57216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Garden Grove
- Michael DaoGarden Grove$843K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.